Anticancer agent that works by depolymerization of microtubules:

Administration of this plant alkaloid anticancer agent is associated with significant incidence of neurotoxicity.

Derivative from the Western Yew and European Yew tree, this anticancer drug acts by enhacing tubulin polymerization.

May be useful in control of metastatic ovarian cancer, this topoisomerase I inhibitor's dose-limiting adverse effects include: neutropenia, thromobcytopenia and anemia.

Active in late S-G2 phase of the cell cycle, the mechanism of this semisynthetic derivative of podophyllotoxin anticancer drug is through inhibition of topoisomerase II.

A patient with fluorouracil-nonresponsive colon cancer is given this prodrug which following activation is a topoisomerase I inhibitor. Following administration, the patient experiences very severe diarrhea which causes hypovolemia. This drug probably was: